Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-Controlled, Double-Blind First in Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-1726 in Participants With Obesity.

NCT06252220 is registered in ClinicalTrials.gov with NeuroBo Pharmaceuticals Inc. as lead sponsor.

NCT NCT06252220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06252220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-Controlled, Double-Blind First in Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-1726 in Participants With Obesity.
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2024
Completion date
November 9, 2026
Enrollment
139 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity